Open AccessHospital-Based Surveillance and Analysis of Genotype Variation in Nicaragua After the Introduction of the Pentavalent Rotavirus Vaccine
Author(s) -
Shazia Khawaja,
Anna Cardellino,
T. Christopher Mast
Publication year - 2014
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000000074
Subject(s) - rotavirus , rotavirus vaccine , genotype , medicine , christian ministry , virology , acute gastroenteritis , vaccination , pediatrics , biology , gene , virus , genetics , philosophy , theology
A live, attenuated, pentavalent rotavirus vaccine (RV5) was introduced in Nicaragua in 2006 through a 3-year partnership between Merck & Co, Inc., and the Nicaraguan Ministry of Health. Nicaragua was the first developing nation to include rotavirus vaccine in its national childhood vaccine program. To monitor the possibility of changing circulating rotavirus strains after the introduction of RV5, we determined the genotypes responsible for rotavirus gastroenteritis-related hospitalization during the first 3 postvaccine years.